Growth hormone shows promise in shrinking HIV's hiding spots

NCT ID NCT03091374

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving recombinant human growth hormone for 48 weeks could reduce the hidden HIV reservoir in people already on successful antiretroviral therapy (ART). The goal was to move toward a 'functional cure' where the body can control the virus without lifelong medication. Twenty-two HIV-positive adults with undetectable viral loads took part. The main focus was on safety and measuring changes in the size of the viral reservoir.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROWTH HORMONE TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mcgill University Health Center

    Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.